{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T04:42:21Z","timestamp":1783399341759,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004366","name":"Tabriz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004366","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102478","type":"journal-article","created":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T18:54:04Z","timestamp":1598813644000},"page":"102478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Pharmacotherapy in multiple sclerosis-induced cognitive impairment: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"46","author":[{"given":"Ali","family":"Motavalli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-4762","authenticated-orcid":false,"given":"Alireza","family":"Majdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahnaz","family":"Talebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javad","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5115-9332","authenticated-orcid":false,"given":"Seyed Hojjat","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-1072","authenticated-orcid":false,"given":"Saeed","family":"Sadigh-Eteghad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"212","key":"10.1016\/j.msard.2020.102478_bib0001","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jep.2017.10.019","article-title":"An ethnopharmacological survey of medicinal plants traditionally used for cancer treatment in the Ashanti region, Ghana","author":"Agyare","year":"2018","journal-title":"J Ethnopharmacol"},{"issue":"260","key":"10.1016\/j.msard.2020.102478_bib0002","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1007\/s00415-012-6678-0","article-title":"Treatment of cognitive impairment in multiple sclerosis: position paper","volume":"6","author":"Amato","year":"2013","journal-title":"J. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2020.102478_bib0003","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1586\/14737175.8.10.1585","article-title":"Cognitive changes in multiple sclerosis","volume":"10","author":"Amato","year":"2008","journal-title":"Expert Rev Neurother"},{"issue":"34","key":"10.1016\/j.msard.2020.102478_bib0004","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10072-012-1265-9","article-title":"Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker","volume":"5","author":"Antonelli","year":"2013","journal-title":"Neurological Sciences"},{"issue":"28","key":"10.1016\/j.msard.2020.102478_bib0005","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.msard.2018.12.026","article-title":"Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: randomized, double-blind, placebo-controlled clinical trial","author":"Arreola-Mora","year":"2019","journal-title":"Preliminary report. Multiple sclerosis and related disorders"},{"key":"10.1016\/j.msard.2020.102478_bib0006","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association, (2013) Diagnostic and statistical manual of mental disorders (DSM-5\u00ae): american Psychiatric Pub.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"52","key":"10.1016\/j.msard.2020.102478_bib0007","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.phymed.2018.06.017","article-title":"Achillea millefolium is beneficial as an add-on therapy in patients with multiple sclerosis: a randomized placebo-controlled clinical trial","author":"Ayoobi","year":"2019","journal-title":"Phytomedicine"},{"issue":"395","key":"10.1016\/j.msard.2020.102478_bib0008","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jns.2018.10.004","article-title":"Long-term effects of prolonged-release fampridine in cognitive function, fatigue, mood and quality of life of MS patients: the IGNITE study","author":"Bakirtzis","year":"2018","journal-title":"J. Neurol. Sci."},{"issue":"12","key":"10.1016\/j.msard.2020.102478_bib0009","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"4","author":"Benedict","year":"2006","journal-title":"J Int Neuropsychol Soc"},{"issue":"12","key":"10.1016\/j.msard.2020.102478_bib0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1017\/S1355617706060723","article-title":"Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)","volume":"4","author":"Benedict","year":"2006","journal-title":"Journal of the International Neuropsychological Society"},{"issue":"255","key":"10.1016\/j.msard.2020.102478_bib0011","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1007\/s00415-008-0760-7","article-title":"Effects of l-amphetamine sulfate on cognitive function in multiple sclerosis patients","volume":"6","author":"Benedict","year":"2008","journal-title":"J. Neurol."},{"issue":"23","key":"10.1016\/j.msard.2020.102478_bib0012","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1177\/1352458517692421","article-title":"Methylphenidate is likely less effective than placebo for improving imbalance, walking, and fatigue in people with multiple sclerosis","volume":"13","author":"Cameron","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"16","key":"10.1016\/j.msard.2020.102478_bib0013","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S1474-4422(17)30113-8","article-title":"Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial","volume":"8","author":"Chan","year":"2017","journal-title":"The Lancet Neurology"},{"issue":"22","key":"10.1016\/j.msard.2020.102478_bib0014","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2165\/00023210-200822020-00001","article-title":"Treatment of cognitive impairment in multiple sclerosis: is the use of acetylcholinesterase inhibitors a viable option?","volume":"2","author":"Christodoulou","year":"2008","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.msard.2020.102478_bib0015","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","article-title":"The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: a Systematic Overview of Meta-Analyses","author":"Claflin","year":"2019","journal-title":"Front Neurol"},{"issue":"372","key":"10.1016\/j.msard.2020.102478_bib0016","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(08)61620-7","article-title":"Multiple sclerosis","volume":"9648","author":"Compston","year":"2008","journal-title":"The Lancet"},{"issue":"86","key":"10.1016\/j.msard.2020.102478_bib0017","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neubiorev.2018.01.006","article-title":"Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: a systematic review and meta-analysis","author":"Cotter","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"issue":"86","key":"10.1016\/j.msard.2020.102478_bib0018","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.neubiorev.2018.01.006","article-title":"Examining the effectiveness of acetylcholinesterase inhibitors and stimulant-based medications for cognitive dysfunction in multiple sclerosis: a systematic review and meta-analysis","author":"Cotter","year":"2018","journal-title":"Neuroscience & Biobehavioral Reviews"},{"issue":"17","key":"10.1016\/j.msard.2020.102478_bib0019","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.msard.2017.08.004","article-title":"Vitamin B12, folate, and homocysteine levels and multiple sclerosis: a meta-analysis","author":"Dardiotis","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"10.1016\/j.msard.2020.102478_bib0020","doi-asserted-by":"crossref","first-page":"45926","DOI":"10.1038\/srep45926","article-title":"Effect of vitamin D replacement on cognition in multiple sclerosis patients","author":"Darwish","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.msard.2020.102478_bib0021","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.2147\/NDT.S87014","article-title":"Serum 25-hydroxyvitamin D predicts cognitive performance in adults","author":"Darwish","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"93","key":"10.1016\/j.msard.2020.102478_bib0022","first-page":"e733","article-title":"Effect of dalfampridine on information processing speed impairment in multiple sclerosis","volume":"8","author":"De Giglio","year":"2019","journal-title":"Neurology"},{"issue":"61","key":"10.1016\/j.msard.2020.102478_bib0023","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1037\/a0039919","article-title":"Cognitive effects of modafinil in patients with multiple sclerosis: a clinical trial","volume":"1","author":"Ford-Johnson","year":"2016","journal-title":"Rehabil Psychol"},{"issue":"53","key":"10.1016\/j.msard.2020.102478_bib0024","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1001\/archneur.1996.00550020101021","article-title":"The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis","volume":"2","author":"Geisler","year":"1996","journal-title":"Arch. Neurol."},{"issue":"71","key":"10.1016\/j.msard.2020.102478_bib0025","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1212\/01.wnl.0000326213.89576.0e","article-title":"Dose comparison trial of sustained-release fampridine in multiple sclerosis","volume":"15","author":"Goodman","year":"2008","journal-title":"Neurology"},{"issue":"276","key":"10.1016\/j.msard.2020.102478_bib0026","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2008.08.025","article-title":"Single dose of methylphenidate improves cognitive performance in multiple sclerosis patients with impaired attention process","volume":"1-2","author":"Harel","year":"2009","journal-title":"J. Neurol. Sci."},{"issue":"17","key":"10.1016\/j.msard.2020.102478_bib0027","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1177\/1352458511412061","article-title":"The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue","volume":"11","author":"Huolman","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"10","key":"10.1016\/j.msard.2020.102478_bib0028","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","article-title":"Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients","author":"Jensen","year":"2016","journal-title":"A randomized, double blind, placebo controlled study. Multiple sclerosis and related disorders"},{"issue":"15","key":"10.1016\/j.msard.2020.102478_bib0029","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ctim.2006.06.005","article-title":"Use of herbal preparations in the treatment of oxidant-mediated inflammatory disorders","volume":"3","author":"Kaplan","year":"2007","journal-title":"Complement Ther Med"},{"issue":"63","key":"10.1016\/j.msard.2020.102478_bib0030","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1212\/01.WNL.0000142989.09633.5A","article-title":"Donepezil improved memory in multiple sclerosis in a randomized clinical trial","volume":"9","author":"Krupp","year":"2004","journal-title":"Neurology"},{"issue":"76","key":"10.1016\/j.msard.2020.102478_bib0031","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1212\/WNL.0b013e318218107a","article-title":"Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis","volume":"17","author":"Krupp","year":"2011","journal-title":"Neurology"},{"issue":"66","key":"10.1016\/j.msard.2020.102478_bib0032","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/gerona\/glq185","article-title":"Vitamin D and cognitive impairment in the elderly US population","volume":"1","author":"Llewellyn","year":"2011","journal-title":"Journals of Gerontology Series A: Biomedical Sciences and Medical Sciences"},{"issue":"13","key":"10.1016\/j.msard.2020.102478_bib0033","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1177\/1352458506071213","article-title":"Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial","volume":"3","author":"Lovera","year":"2007","journal-title":"Mult. Scler."},{"issue":"79","key":"10.1016\/j.msard.2020.102478_bib0034","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1212\/WNL.0b013e31826aac60","article-title":"Ginkgo biloba does not improve cognitive function in MS: a randomized placebo-controlled trial","volume":"12","author":"Lovera","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.msard.2020.102478_bib0035","doi-asserted-by":"crossref","first-page":"e01086","DOI":"10.1002\/brb3.1086","article-title":"Estriol\u2010mediated neuroprotection in multiple sclerosis localized by voxel\u2010based morphometry","volume":"9","author":"MacKenzie\u2010Graham","year":"2018","journal-title":"Brain Behav"},{"issue":"62","key":"10.1016\/j.msard.2020.102478_bib0036","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1212\/01.WNL.0000129263.14219.A8","article-title":"Enhanced brain motor activity in patients with MS after a single dose of 3, 4-diaminopyridine","volume":"11","author":"Mainero","year":"2004","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.msard.2020.102478_bib0037","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.hermed.2016.05.003","article-title":"Effect of Boswellia serrata on cognitive impairment in multiple sclerosis patients","volume":"3","author":"Majdinasab","year":"2016","journal-title":"J Herb Med"},{"issue":"19","key":"10.1016\/j.msard.2020.102478_bib0038","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1177\/1352458512463481","article-title":"Randomised multicentre trial on safety and efficacy of rivastigmine in cognitively impaired multiple sclerosis patients","volume":"5","author":"Maurer","year":"2013","journal-title":"Mult. Scler."},{"issue":"99","key":"10.1016\/j.msard.2020.102478_bib0039","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.neuropharm.2015.07.013","article-title":"Polymerized nano-curcumin attenuates neurological symptoms in EAE model of multiple sclerosis through down regulation of inflammatory and oxidative processes and enhancing neuroprotection and myelin repair","author":"Mohajeri","year":"2015","journal-title":"Neuropharmacology"},{"issue":"17","key":"10.1016\/j.msard.2020.102478_bib0040","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1177\/1352458511402410","article-title":"HAGIL (Hamburg Vigil Study): a randomized placebo-controlled double-blind study with modafinil for treatment of fatigue in patients with multiple sclerosis","volume":"8","author":"Moller","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"issue":"256","key":"10.1016\/j.msard.2020.102478_bib0041","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1007\/s00415-009-5074-x","article-title":"The effects of l-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial","volume":"7","author":"Morrow","year":"2009","journal-title":"J. Neurol."},{"issue":"232","key":"10.1016\/j.msard.2020.102478_bib0042","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1007\/s00213-015-4051-6","article-title":"Effects of single dose mixed amphetamine salts - Extended release on processing speed in multiple sclerosis: a double blind placebo controlled study","volume":"23","author":"Morrow","year":"2015","journal-title":"Psychopharmacology (Berl.)"},{"issue":"11","key":"10.1016\/j.msard.2020.102478_bib0043","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.msard.2016.10.011","article-title":"The effect of Fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS","author":"Morrow","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"260","key":"10.1016\/j.msard.2020.102478_bib0044","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00415-012-6663-7","article-title":"Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study","volume":"2","author":"Morrow","year":"2013","journal-title":"J. Neurol."},{"issue":"139","key":"10.1016\/j.msard.2020.102478_bib0045","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.clineuro.2015.08.023","article-title":"Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients","author":"Pavsic","year":"2015","journal-title":"Clin Neurol Neurosurg"},{"issue":"363","key":"10.1016\/j.msard.2020.102478_bib0046","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jns.2016.02.012","article-title":"Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study","author":"Peyro Saint Paul","year":"2016","journal-title":"J. Neurol. Sci."},{"issue":"14","key":"10.1016\/j.msard.2020.102478_bib0047","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1177\/1352458508095004","article-title":"Cognitive impairments in relapsing-remitting multiple sclerosis: a meta-analysis","volume":"9","author":"Prakash","year":"2008","journal-title":"Multiple Sclerosis Journal"},{"issue":"26","key":"10.1016\/j.msard.2020.102478_bib0048","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1177\/1352458518815795","article-title":"Dalfampridine benefits ambulation but not cognition in multiple sclerosis","volume":"1","author":"Satchidanand","year":"2020","journal-title":"Multiple Sclerosis Journal"},{"issue":"36","key":"10.1016\/j.msard.2020.102478_bib0049","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1097\/MRR.0b013e32835c79ea","article-title":"Factors related to difficulties with employment in patients with multiple sclerosis: a review of 2002-2011 literature","volume":"2","author":"Schiavolin","year":"2013","journal-title":"International Journal of Rehabilitation Research Internationale Zeitschrift fur Rehabilitationsforschung Revue Internationale de Recherches de Readaptation"},{"issue":"23","key":"10.1016\/j.msard.2020.102478_bib0050","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/1352458516661048","article-title":"High-dose erythropoietin in patients with progressive multiple sclerosis: a randomized, placebo-controlled, phase 2 trial","volume":"5","author":"Schreiber","year":"2017","journal-title":"Multiple Sclerosis Journal"},{"issue":"13","key":"10.1016\/j.msard.2020.102478_bib0051","first-page":"149","article-title":"Effect of Boswellia papyrifera on cognitive impairment in multiple sclerosis","volume":"3","author":"Sedighi","year":"2014","journal-title":"Iran J Neurol"},{"issue":"35","key":"10.1016\/j.msard.2020.102478_bib0052","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1017\/S0317167100009148","article-title":"Effects of rivastigmine on memory and cognition in multiple sclerosis","volume":"4","author":"Shaygannejad","year":"2008","journal-title":"The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques"},{"issue":"93","key":"10.1016\/j.msard.2020.102478_bib0053","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1212\/WNL.0000000000007964","article-title":"Dalfampridine improves slowed processing speed in MS","volume":"8","author":"Sumowski","year":"2019","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2020.102478_bib0500","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1177\/1352458511404585","article-title":"L-amphetamine improves memory in MS patients with objective memory impairment","volume":"17","author":"Sumowski","year":"2011","journal-title":"Multiple Sclerosis Journal"},{"key":"10.1016\/j.msard.2020.102478_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102172","article-title":"The Cambridge Neuropsychological Test Automated Battery (CANTAB) Versus the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) for the Assessment of Cognitive Function in Patients with Multiple Sclerosis","author":"Talebi","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"17","key":"10.1016\/j.msard.2020.102478_bib0055","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1177\/1352458511399613","article-title":"Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment","volume":"8","author":"Virta","year":"2011","journal-title":"Multiple Sclerosis Journal"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305538?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305538?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:57:29Z","timestamp":1761901049000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305538"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":56,"alternative-id":["S2211034820305538"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102478","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacotherapy in multiple sclerosis-induced cognitive impairment: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102478"}}